Safety, Tolerability and Efficacy for CGF166 in Patients With Bilateral Hearing Loss

To evaluate CGF166 delivered through IL-infusion to improve hearing and vestibular function.

  1. Tinnitus Talk
    The goal of the current study is to evaluate the safety, tolerability, and the potential ability of CGF166 delivered through IL-infusion to improve hearing and vestibular function. CGF166 is a recombinant adenovirus 5 (Ad5) vector containing a cDNA encoding the human Atonal transcription factor (Hath1).

    Estimated Enrollment: 45
    Study Start Date: June 2014
    Estimated Study Completion Date: August 2017
    Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
Donate to Tinnitus Talk